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Cartilage Oligomeric Matrix Protein Associates
Differentially with Erosions and Synovitis and Has a
Different Temporal Course in Cyclic Citrullinated
Peptide Antibody (Anti-CCP)-positive versus 
Anti-CCP-negative Early Rheumatoid Arthritis
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BO EJBJERG, KRISTIAN STENGAARD-PEDERSEN, SØREN JACOBSEN, TINE LOTTENBURGER, 
TORKELL ELLINGSEN, LIS S. ANDERSEN, IB HANSEN, HENRIK SKJØDT, JENS K. PEDERSEN, 
ULRIK B. LAURIDSEN, ANDERS SVENDSEN, ULRIK TARP, JAN PØDENPHANT, MIKKEL ØSTERGAARD, 
and PETER JUNKER
ABSTRACT. Objective. Cyclic citrullinated peptide antibody (anti-CCP)-positive and anti-CCP-negative rheumatoid
arthritis (RA) have been suggested as 2 distinctive disease subsets with respect to disease activity and
prognosis. Previously, we proposed that anti-CCP antibodies might have a chondrocyte-suppressive
effect. We aimed to compare circulating cartilage oligomeric matrix protein (COMP), a marker of carti-
lage turnover, in untreated anti-CCP-positive and anti-CCP-negative RA, and to study the temporal pat-
tern of COMP through 4 years of treatment, including the relationship to imaging and clinical findings.
Methods. A total of 160 patients with newly diagnosed RA who were naive to disease-modifying
antirheumatic drugs were included in the CIMESTRA trial. Ninety healthy blood donors served as con-
trols. Demographic and disease measures including Disease Activity Score in 28 joints, IgM rheuma-
toid factor, anti-CCP, Health Assessment Questionnaire, visual analog scale scores for pain and global
and physician assessment, and magnetic resonance imaging (MRI) of the nondominant hand were
recorded at baseline. COMP in serum was measured by ELISA at inclusion and serially through 4 years.
Results. Median baseline COMP was higher in patients with RA [9.8 U/l (interquartile range 8.96,
10.5)] compared with controls [8.3 U/l (IQR 7.84, 8.9); p < 0.001] and remained elevated at 4 years
[10.8 U/l (IQR 10.2, 11.7); p < 0.001]. At baseline, anti-CCP-positive patients had lower COMP than
anti-CCP-negative patients (p = 0.048). In anti-CCP-positive patients, COMP exhibited a parabolic
course over 4 years, while COMP in anti-CCP-negative patients had an almost linear course. In 
anti-CCP-positive patients, COMP was associated with MRI edema and erosion score, while COMP
was correlated with synovitis score in anti-CCP-negative individuals.
Conclusion. Our study provides additional evidence for the existence of different disease pathways in
anti-CCP-positive and anti-CCP-negative subsets of RA, and evidence that anti-CCP antibodies may be
implicated in the disease process by modifying cartilage metabolism. (First Release May 15 2011; 
J Rheumatol 2011;38:1563–8; doi:10.3899/jrheum.101241)
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Cartilage oligomeric matrix protein (COMP), a member of the
thrombospondin glycoprotein family, is an extracellular
matrix protein mainly expressed in cartilaginous tissue1,2,3.
Excess release of COMP leading to elevated levels in serum
has been reported in various joint diseases, osteoarthritis and
rheumatoid arthritis (RA) in particular4. While some studies
have suggested that increased COMP in the circulation is a
predictor of joint destruction of large5 and small joints6,7 in
RA, discrepant results have been reported by others8,9,10.
These disparities may be attributable to differences in the
study populations, e.g., with respect to cyclic citrullinated
peptide antibody (anti-CCP) seropositivity. Thus, Turesson, et
al recently reported increased COMP levels in individuals
who developed RA within 1–2 years, and elevated COMP 
was more likely in anti-CCP-negative subjects than in
anti-CCP-posi tive individuals11. We recently reported that the
N-propeptide of collagen IIA (PIIANP), a marker of cartilage
collagen anabolism, is significantly lower in anti-CCP-posi-
tive compared to anti-CCP-negative patients with RA12. As
well, we found a negative correlation between PIIANP and
anti-CCP titer in serum12. These observations indicate that
autoimmunity reflected by anti-CCP is implicated in the
pathogenesis of RA by suppressing collagen II formation.
Since COMP in serum is widely considered to be a reliable
molecular marker of cartilage turnover, we undertook this
investigation in order to compare circulating COMP in newly
diagnosed, untreated anti-CCP-positive versus anti-CCP-neg-
ative RA; to elucidate the temporal COMP pattern in these 2
subsets; and to study the relationship between COMP and
baseline magnetic resonance imaging (MRI) findings and dis-
ease activity measures.
MATERIALS AND METHODS
Patients and controls. A total of 160 patients with newly diagnosed untreated
RA were included in the CIMESTRA trial13. Briefly, patients fulfilled the
American College of Rheumatology (ACR) 1987 revised criteria for RA14.
Further inclusion criteria were disease duration < 6 months, ≥ 2 swollen joints
at baseline, and age 18–75 years. Health Assessment Questionnaire (HAQ
score, 0–3)15, visual analog scale (VAS; 1–10) for pain and global and physi-
cian assessment, and Disease Activity Score in 28 joints (DAS28)16 were cal-
culated and ACR response was recorded17. Ninety healthy blood donors (45
women, 45 men; median age 42.5 yrs, range 23–64 yrs) served as controls. In
this healthy cohort, no other biochemical or clinical data were available and
COMP was measured only once.
The RA treatment strategy aimed at achieving maximal synovitis control
using methotrexate (MTX) plus cyclosporine compared to MTX and place-
bo13. In addition, patients in both groups received intraarticular betametha-
sone injections into swollen joints (7 mg/l, maximum 4 joints or 4 ml per
visit). After one year, hydroxychloroquine was added and cyclosporine/place-
bo was tapered to zero, while MTX and synovitis suppression by intraarticu-
lar steroid injections into swollen joints were continued13. During an open
extension through study years 3–4 the strategy of maximal synovitis suppres-
sion was pursued18. Oral glucocorticoids were allowed during the open exten-
sion study.
The trial was approved by the local ethics committee (j. no. M1959-98) and ful-
filled the Declaration of Helsinki and the International Conference on Harmonisation
1996 revised guidelines for Good Clinical Practice (j. no. NCT00209859)13.
Signed informed consent was obtained from all study  participants.
Imaging. At baseline, 135 patients underwent contrast enhanced MRI of the
nondominant wrist prior to treatment initiation. In 93 patients, 2nd-5th
metacarpophalangeal (MCP) joints were imaged as well. A 0.2 Tesla dedicat-
ed extremity MRI unit (Artoscan, Esaote, Biomedica, Genova, Italy) was
used in 91 patients, whereas a 1.0 Tesla and a 1.5 Tesla whole-body MRI unit
(Siemens Impact and Siemens Vision, Erlangen, Germany) were used in 44
patients. MRI sequences included coronal and axial T1-weighted images
(slice thickness 3 mm; matrix 192 × 192–384) before and after intravenous
gadolinium-contrast injection (0.1 mmol gadolinium DTPA-BMA/kg body
weight; Omniscan, Amersham Health, Copenhagen, Denmark); and a coronal
short-tau inversion recovery (STIR) sequence (slice thickness 3 mm, matrix
size 144–182 × 192–256)19. MRI synovitis, edema, and erosion scores were
assessed according to the OMERACT criteria20.
Laboratory measures. Serum was obtained from routine nonfasting blood
samples collected between 8:00 A.M. and 2:00 P.M. Samples were allowed to
clot at room temperature followed by centrifugation at 3000 g for 10 min.
Sera were stored at –80°C. COMP was measured in serum by a sandwich
ELISA at baseline, after 1, 3 and 6 months, and after 1 and 4 years. The
ELISA, based on 2 monoclonal antibodies directed against antigen determi-
nants on the COMP molecule, was developed by AnaMar Medical AB,
Gotenburg, Sweden21.
The reference range in our laboratory was 4.3–22.3 U/l. The interassay
coefficients of variation were 11.9% and 9.8% for low (4.8–7.6 U/l) and high
(9.1–14.9 U/l) concentration controls, respectively. The intraassay coeffi-
cients were < 2.5%. All analyses were done in duplicate. Serial patient sera
were assayed simultaneously.
C-reactive protein (mg/l) and erythrocyte sedimentation rate (mm/h) were
measured using standard laboratory methods. IgM rheumatoid factor 
(IgM-RF; cutoff level 16 IU/ml) and anti-CCP (cutoff level 24 U/ml22;
EuroDiagnostica AB, Malmö, Sweden) were measured by ELISA as report-
ed22,23,24. Anti-CCP and RF status were not available for 1 patient.
Genomic DNA was isolated from EDTA-stabilized whole-blood samples.
Human leukocyte antigen (HLA)-DRB1 genotyping for shared epitope (SE)
was performed by polymerase chain reaction-based sequence-specific
oligonucleotide probing, as described25. We define the SE as the presence of
HLA-DRB1*04 and/or HLA-DRB1*01 and/or HLA-DRB1*10.
Statistics. All analyses were performed in Stata 9.2 (Stata Corp., College
Station, TX, USA). Fisher’s exact test and Mann-Whitney U test were used to
compare groups for dichotomous and nondichotomous data, respectively.
Linear regression modeling with adjustment for time, time-squared, sex, and
age at baseline was used to analyze the course of COMP (y = ß0 + ßlncomp +
ßtime + ßtime
2 + ßage + ßsex).
Comparison between patients and controls at each timepoint was by lin-
ear regression modeling with adjustment for sex and age. Robust estimation
of standard error was calculated. COMP was logarithmically transformed to
approximate normal distribution. Spearman rank correlation analysis was used
when appropriate. Since COMP did not differ between the 2 treatment arms,
data from all the patients were pooled. Analysis was by intention-to-treat (n =
145). Analysis of completers was also performed and gave similar results.
Missing values were assumed to be missing at random. All values are pre-
sented as median [interquartile range (IQR)] if not otherwise reported. 
P  values < 0.05 were considered statistically significant.
RESULTS
Patients and controls. Sixty-one patients (38%) failed to com-
plete 4 years of followup; the reasons for discontinuation were
adverse events (11), lack of efficacy (10), patient’s request
(13), and other (27). Fifty-six (35%) dropped out during the
first 2 years. Patients who dropped out did not differ from
completers with regard to demographic and clinical variables
at baseline (data not shown).
Baseline characteristics in the RA population were as
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described13,26. The 2 treatment arms did not differ in baseline
characteristics except for a higher proportion of 
anti-CCP-positive patients in the MTX/cyclosporine versus
the MTX/placebo group (57/80 vs 36/80; p < 0.001). The
need for glucocorticoids was higher during the first 2 years
compared with the open extension study18. During the open
extension study the cumulative dose of glucocorticoids cor-
responded to 0.09 (IQR 0–0.38) mg prednisolone per day
(intraarticular and oral) compared to 0.97 (0.5–1.7) mg per
day the first 2 years18. There was no difference in the cumu-
lative doses of intraarticular betamethasone administered
during the first 2 years between the 2 treatment arms
[MTX/placebo vs MTX/cyclosporine: 14.4 ml (7.5–19.8) vs
11 ml (7–17.1); p = 0.10]. The cumulative dose was signifi-
cantly higher during the first year compared with the sub -
sequent years26. Similarly, no difference was observed
between anti-CCP-positive and anti-CCP-negative patients
with respect to the total intraarticular glucocorticoid dose
[12 ml (8.1–21.3) vs 12 ml (7–19); p = 0.37]. Including the
cumulative dose of steroids used in the open extension study,
again no difference was observed between the treatment
arms or anti-CCP status (data not shown). In the RA popula-
tion there was a statistically significant female preponder-
ance (107/160 vs 45/90; p = 0.01), and the RA patients were
older than the controls [52.9 (41.8–62.5) yrs vs 42.5 (31–53)
yrs; p < 0.001].
One hundred thirty-four patients had data available for
composite disease activity measures at 4-year followup, and
103/134 (77%), 86/134 (64%), and 89/134 (66%) achieved
ACR50, ACR70, and DAS28 < 2.6, respectively.
COMP in serum. COMP exhibited an age-dependent increase
in RA patients and healthy controls (rho = 0.29, p = 0.0002,
and rho = 0.27, p = 0.01, respectively). Further, the level of
COMP was significantly higher among male compared to
female patients with RA [11.5 U/l (IQR 9.4–13.5) vs 8.9 U/l
(7.8–11); p < 0.001]. There was no significant difference in
COMP levels between the sexes in controls [8.5 U/l
(7.6–10.4) vs 8.0 U/l (7.3–9.4); p = 0.13].
At baseline, circulating COMP was increased in RA
patients compared to controls [9.8 U/l (IQR 8.1–12.1) vs 8.3
U/l (7.4–9.8); p < 0.001], even adjusted for age and sex (p =
0.001). COMP remained elevated at 4 years [10.8 (8.5–13.7);
p < 0.001]. Stratification according to anti-CCP status
showed that this increase applied to both subsets, but that
COMP was significantly lower in anti-CCP-positive versus
anti-CCP-negative patients [9.0 U/l (7.8–11.8) vs 10.5 U/l
(8.4–13.1); p = 0.048; Figure 1]. The same trend was
observed after 4 years [10.2 U/l (8.3–13.4) vs 11.7 U/l
(9.6–14.3); p = 0.055].
At baseline, COMP was also lower among IgM-RF-posi-
tive compared to IgM-RF-negative patients [9.1 U/l (IQR
7.8–11.8) vs 10.1 U/l (8.6–13.3); p = 0.047].
An inverse correlation was observed between COMP and
anti-CCP titer at baseline (rho = –0.17, p = 0.03). No differ-
ence in COMP was observed regarding shared epitope status
(p = 0.26) or smoking status (p = 0.61).
There was no difference in baseline COMP values between
patients who achieved DAS28 < 2.6 (p = 0.48) or ACR70
response (p = 0.21) compared with patients who did not
achieve DAS28 < 2.6 or ACR70 response after 4 years.
There was no difference between anti-CCP-positive and
anti-CCP-negative patients with respect to demographic or clin-
ical variables, except that anti-CCP-positive patients had fewer
tender joints [8 (5–15) vs 11 (7–16); p = 0.02] and were more
frequently carriers of the SE [82/93 (88%) vs 34/65 (52%); p <
0.001] compared with anti-CCP-negative individuals.
The associations between baseline COMP and clinical
variables at baseline are outlined in Table 1.
The temporal course of COMP in RA serum exhibited a
parabolic configuration (Figure 2A; ßtime
2 = –8.37 × 10–6, p =
0.004) irrespective of age and sex (data not shown). This par-
abolic course was confined to the anti-CCP-seropositive sub-
set (ßtime
2 = –1.3 × 10–5, p = 0.001), while an almost linear
course was observed in anti-CCP-negative subjects (ßtime
2 =
–1.3 × 10–6, p = 0.77; Figure 2B).
From baseline and 12 months onward, COMP increased in
anti-CCP-positive patients [9 U/l (IQR 7.8–11.8) vs 11.3 U/l
(8.6–14); p < 0.001], while there was no significant difference
in anti-CCP-negative subjects during this period [10.5 U/l
(8.4–13.1) vs 11.3 U/l (8.7–13.7); p = 0.55]. Although not sta-
tistically significant, COMP tended to decrease from years 1
through 4 in anti-CCP-positive patients [11.3 U/l (8.6–14) vs
1565Christensen, et al: COMP, anti-CCP, RA
Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.
Figure 1. Circulating cartilage oligomeric matrix protein (COMP) in controls
and patients with anti-CCP-positive and anti-CCP-negative newly diagnosed
untreated RA. Boxes show median and interquartile range; whiskers denote
5th and 95th percentiles. Dots are outliers. *Anti-CCP-positive versus
anti-CCP-negative, p = 0.048 (adjusted for sex and age, p = 0.009). 
**Anti-CCP-positive versus controls, p = 0.006 (adjusted for sex and age, 
p = 0.04). #Anti-CCP-negative versus controls, p < 0.001 (adjusted for sex
and age, p < 0.001).
 Journal of Rheumatology
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10.2 U/l (8.3–13.4); p = 0.82). This trend was not observed
among anti-CCP-negative individuals.
COMP and imaging data. The wrist-only MRI group (n =
135) and the wrist+MCP MRI group (n = 93) did not differ in
baseline variables including anti-CCP status19. Baseline
COMP correlated significantly, although weakly, with MRI
wrist-only erosion and synovitis scores (rho = 0.25, p =
0.0043, and rho = 0.25, p = 0.0039, respectively). Stratifying
the cohort according to anti-CCP status, COMP correlated sim-
ilarly to the erosion score in anti-CCP-positive individuals (n =
81) but not in anti-CCP-negative individuals (n = 53; Table 1).
By contrast, COMP was weakly associated with synovitis
score in anti-CCP-negative individuals (Table 1). In the
wrist+MCP MRI group the same trend was observed for the
erosion score [anti-CCP-positive (n = 53): rho = 0.28, p = 0.04;
and anti-CCP-negative (n = 36): rho = 0.14, p = 0.40], but not
for the synovitis score (data not shown). The MRI edema score
was associated with COMP in the anti-CCP-positive patients
in the wrist-only and wrist+MCP MRI groups (rho = 0.26, p =
0.017, and rho = 0.32, p = 0.016, respectively).
DISCUSSION
In this study, we add to previous evidence that COMP in the
circulation is increased in patients with newly diagnosed RA.
Of note, however, this increment was less pronounced in 
anti-CCP-positive compared to anti-CCP-negative individu-
als, and in addition, there was an inverse correlation between
COMP in serum and anti-CCP titer. Further, we found that in
anti-CCP-positive individuals, circulating COMP followed a
parabolic 4-year course, whereas there was an almost linear
pattern in anti-CCP-negative patients. In anti-CCP-positive
patients, COMP was associated with MRI erosion and edema
score, while COMP correlated positively with MRI synovitis
scores in anti-CCP-negative subjects.
Our finding of lower COMP in anti-CCP-positive com-
pared with anti-CCP-negative patients is in accord with a
recent report by Turesson, et al11. These authors reported that
individuals who developed RA had higher prediagnostic
COMP levels 1–2 years before RA diagnosis compared with
matched controls, but that this increment was particularly
prevalent in anti-CCP-negative preclinical RA11.
In a study on the N-propeptide of collagen IIA (PIIANP), a
marker of collagen II anabolism, we found that circulating
PIIANP was significantly lower in anti-CCP-positive com-
pared to anti-CCP-negative patients with RA12. In addition,
there was a negative correlation between PIIANP and 
anti-CCP titer. These observations support the thesis that anti-
bodies against citrullinated peptides may have a cartilage-sup-
pressive effect. This is supported by chondrocyte culture stud-
ies and animal experiments, where antibodies against citrulli-
nated peptides, e.g., collagen II and fibrinogen, have been
reported to induce arthritis and to aggravate preexisting exper-
imental arthritis27,28,29. Considering that bone marrow edema
has been shown to be a strong predictor of future erosive pro-
gression18,19, the potential pathogenicity of anti-CCP is fur-
ther supported in this study, where we report a positive corre-
lation between COMP and MRI edema and erosion scores in
patients who are anti-CCP-positive. Further evidence for dif-
ferential pathogenic pathways in anti-CCP-positive and anti-
CCP-negative RA patients appears from the correlation
between COMP and MRI synovitis scores and not erosion
scores in anti-CCP-negative subjects observed in our study.
The CIMESTRA treatment protocol on which this study is
based has been reported to be particularly efficient with
respect to suppression of signs and symptoms of RA and ero-
sive progression13,18,26. Since COMP is considered to be an
integral component in cartilage growth and regeneration30,31,
it would be anticipated that suppression of joint inflammation
would lead to increased formation and release of COMP into
the circulation. This is supported by the COMP increment fol-
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Table 1. Associations between cartilage oligomeric matrix protein (COMP) and clinical variables at baseline in
patients with early untreated rheumatoid arthritis. Spearman rank correlation rho values.
Characteristic COMP at Baseline, COMP at Baseline, COMP at Baseline,
n = 160 Anti-CCP-positive, Anti-CCP-negative,
n = 93 n = 66
C-reactive protein 0.10 0.13 0.14
DAS28 0.28** 0.28** 0.27*
No. swollen joints 0.39** 0.32** 0.47**
No. tender joints 0.29** 0.27** 0.26*
MRI synovitis score† 0.25** 0.22* 0.32*
MRI erosion score† 0.25** 0.37** 0.13
MRI edema score† 0.18* 0.26* 0.14
HAQ 0.11 0.20 0.04
VAS global 0.07 0.10 0.05
VAS pain 0.09 0.17 –0.02
VAS physician 0.34** 0.25* 0.44**
* p ≤ 0.05; ** p ≤ 0.01. † Contrast-enhanced MRI of nondominant wrist (n = 135). CCP: cyclic citrullinated pep-
tides; DAS28: Disease Activity Score including 28 joints; VAS: visual analog scale score; HAQ: Health
Assessment Questionnaire.
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lowing initiation of synovitis-suppressive treatment (Figure
2A). However, the parabolic course in the anti-CCP-positive
subset, which exhibited a peak value followed by gradual
decline through years 1–4, probably reflects that complete
regeneration of cartilage metabolism cannot be achieved
despite early and aggressive treatment. Thus, the lower
COMP in longstanding RA among anti-CCP-positive individ-
uals may reflect a modifier effect by these autoantibodies on
cartilage metabolism. Alternatively, these different patterns
may reflect that increased cartilage turnover occurs in a sub-
set that is distinct from the RA phenotype characterized by
anti-CCP, and that COMP may have different implications in
these 2 disease categories. In addition, in anti-CCP-positive
patients, paracrine and/or autocrine signaling from the jux-
taarticular bone compartment may contribute to cartilage
depletion, as shown by the baseline association between
COMP and MRI edema score in anti-CCP-seropositive
patients. The potential significance of anti-CCP antibodies is
emphasized by the observation that COMP did not differ
according to shared epitope status or smoking habit. This indi-
cates that anti-CCP antibodies interfere with RA disease
mechanisms that are not shared with these well established
risk factors for RA.
The study has some limitations and issues to be considered.
First, COMP was measured only once in the control cohort,
implying that potential temporal changes related to, for exam-
ple, age or future health status are missed. Second, approxi-
mately 40% failed to complete the study followup. However,
there was no difference with respect to baseline characteristics
between completers and noncompleters and the inten -
tion-to-treat analysis included a large majority of the cohort.
Third, the CIMESTRA cohort was offered intraarticular
betamethasone injections whenever swollen joints were pres-
ent. Hence, the different temporal courses of COMP accord-
ing to anti-CCP status could in theory be attributable to dif-
ferent steroid dosing in the 2 subsets. However, no difference
was observed between the 2 subsets with respect to their
cumulative steroid doses.
Our study provides further evidence for the existence of
different disease pathways between anti-CCP-positive and
anti-CCP-negative subsets of RA, and evidence that anti-CCP
antibodies may be implicated in the disease process by modi-
fying cartilage metabolism.
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